This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kite Pharma, Inc.
Drug Names(s): HPV-16 E6 T cell receptor
Description: E6 TCR is a T Cell Receptor (TCR)-based product candidate directed against the human papillomavirus (HPV)-16 E6 oncoprotein.
Kite and NIH
In January 2015, Kite Pharma announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to T Cell Receptor (TCR)-based product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of cancers associated with HPV infection. Pursuant to the terms of the license agreement, Kite will make to NIH certain clinical, regulatory, and sales milestone payments and royalties on net sales of products covered by the license.
Partners: National Institutes of Health (NIH)
E6 TCR News
Additional information available to subscribers only: